Time filter

Source Type

Donia M.,Center for Cancer Immune Therapy | Donia M.,Copenhagen University | Kimper-Karl M.L.,University of Southern Denmark | Hoyer K.L.,Aarhus University Hospital | And 4 more authors.
European Journal of Cancer | Year: 2017

Background Recent randomised phase III trials have led to the approval of several immune checkpoint inhibitors for unresectable or metastatic melanoma (MM). These trials all employed strict patient selection criteria, and it is currently unknown how large proportion of ‘real-world’ patients diagnosed with MM is not represented in these trials. Patients and methods The Danish MM Database contains data on the entire, unselected population of MM within a nationwide geographical area. A total of 276 unselected cases of MM (ocular melanoma excluded), referred for first oncological evaluation in 2014, were included in the analysis. Seven pre-defined eligibility criteria, all used to select patients for enrolment in five recent randomised phase III immunotherapy trials, were analysed. Results Fifty-five percent of the total population with MM did not meet one or more eligibility criteria (‘not eligible’ group) at first evaluation. PS ≥ 2 or active/untreated known brain metastases accounted alone for 74% of non-eligibility cases. Median overall survival in the ‘not eligible’ group was 5.43 months versus 18.3 months for the eligible (p < 0.0001, hazard ratio (HR) 2.44), reflected by significantly worse baseline prognostic features. However, patients treated with immunotherapy had similar survival outcomes regardless of eligibility. Conclusion Over half of the patients evaluated for systemic treatment of MM are not represented in phase III registration immunotherapy trials. The data reveal a huge knowledge gap regarding the usefulness of new immunotherapies in the ‘real-world’ patient population, and urge additional testing of known regimens in selected poor prognosis cohorts. © 2017 Elsevier Ltd

Donia M.,Center for Cancer Immune Therapy | Donia M.,Herlev Hospital | Donia M.,University of Catania | Larsen S.M.,Center for Cancer Immune Therapy | And 4 more authors.
Cytotherapy | Year: 2014

Background aims: The high level of complexity of current Good Manufacturing Practice-compliant methods of manufacturing hampers rapid and broad application of treatment with tumor-infiltrating lymphocytes (TILs). Methods: To ensure higher applicability of TIL production to laboratory routine, a practical and simple protocol of TIL manufacturing with the use of a closed-system bioreactor was developed and implemented at our institution. Results: This protocol enabled significant work load reduction during the most labor-intense step of TIL expansion, and allowed generation of high-quality TIL products, which mediated clinical regression in patients with metastatic melanoma. Conclusions: Implementation of simplified methods of TIL expansion will speed up dissemination of TIL methods worldwide and will increase patient access to this highly effective treatment. © 2014 International Society for Cellular Therapy.

Loading Center for Cancer Immune Therapy collaborators
Loading Center for Cancer Immune Therapy collaborators